clinical trial · NCT00836056
Clindamycin 300 mg Capsules in Healthy Subjects Under Fasting Conditions
Teva Pharmaceuticals USA·phase1·completed·n = 24
HealthyClindamycin 300 mg capsuleCleocin HCl 300 mg capsules
brief summary
The objective of this study is to compare the rate and extent of absorption of clindamycin 300 mg capsules (test) versus Cleocin HCl (reference), administered as 1 x 300 mg capsule under fasting conditions.
started
Nov 1, 2003
primary completion
Nov 1, 2003
completion
Nov 1, 2003
last updated
Aug 19, 2024
detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
official title
Randomized, 2-Way Crossover, Bioequivalence Study of Clindamycin 300 mg Capsules and Cleocin HCl Administered as 1 x 300 mg Capsule in Healthy Subjects Under Fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol